138 related articles for article (PubMed ID: 36870603)
41. Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders.
Ladetto M; Brüggemann M; Monitillo L; Ferrero S; Pepin F; Drandi D; Barbero D; Palumbo A; Passera R; Boccadoro M; Ritgen M; Gökbuget N; Zheng J; Carlton V; Trautmann H; Faham M; Pott C
Leukemia; 2014 Jun; 28(6):1299-307. PubMed ID: 24342950
[TBL] [Abstract][Full Text] [Related]
42. Rearranged T-cell receptor beta genes represent powerful targets for quantification of minimal residual disease in childhood and adult T-cell acute lymphoblastic leukemia.
Brüggemann M; van der Velden VH; Raff T; Droese J; Ritgen M; Pott C; Wijkhuijs AJ; Gökbuget N; Hoelzer D; van Wering ER; van Dongen JJ; Kneba M
Leukemia; 2004 Apr; 18(4):709-19. PubMed ID: 14961040
[TBL] [Abstract][Full Text] [Related]
43. Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia.
Faham M; Zheng J; Moorhead M; Carlton VE; Stow P; Coustan-Smith E; Pui CH; Campana D
Blood; 2012 Dec; 120(26):5173-80. PubMed ID: 23074282
[TBL] [Abstract][Full Text] [Related]
44. [Gene rearrangement pattern of immunoglobulin and T-cell receptor (Ig/TR) and its clinical characteristics in children with SET-NUP214 fusion gene-positive leukemia/lymphoma].
Li WJ; Cui L; Gao C; Zhao XX; Liu SG; Xin YP; Zhang RD; Zhang DW; Wang B; Li ZG; Wu MY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Dec; 19(6):1362-7. PubMed ID: 22169284
[TBL] [Abstract][Full Text] [Related]
45. In vitro amplification of T cell gamma gene rearrangements: a new tool for the assessment of minimal residual disease in acute lymphoblastic leukemias.
d'Auriol L; Macintyre E; Galibert F; Sigaux F
Leukemia; 1989 Feb; 3(2):155-8. PubMed ID: 2536129
[TBL] [Abstract][Full Text] [Related]
46. Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk after Autologous Hematopoietic Stem Cell Transplantation.
Mannis GN; Martin TG; Damon LE; Andreadis C; Olin RL; Kong KA; Faham M; Hwang J; Ai WZ; Gaensler KML; Sayre PH; Wolf JL; Logan AC
Biol Blood Marrow Transplant; 2016 Jun; 22(6):1030-1036. PubMed ID: 26899561
[TBL] [Abstract][Full Text] [Related]
47. Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies.
van Dongen JJ; van der Velden VH; Brüggemann M; Orfao A
Blood; 2015 Jun; 125(26):3996-4009. PubMed ID: 25999452
[TBL] [Abstract][Full Text] [Related]
48. IMonitor: A Robust Pipeline for TCR and BCR Repertoire Analysis.
Zhang W; Du Y; Su Z; Wang C; Zeng X; Zhang R; Hong X; Nie C; Wu J; Cao H; Xu X; Liu X
Genetics; 2015 Oct; 201(2):459-72. PubMed ID: 26297338
[TBL] [Abstract][Full Text] [Related]
49. Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol.
Van der Velden VH; Corral L; Valsecchi MG; Jansen MW; De Lorenzo P; Cazzaniga G; Panzer-Grümayer ER; Schrappe M; Schrauder A; Meyer C; Marschalek R; Nigro LL; Metzler M; Basso G; Mann G; Den Boer ML; Biondi A; Pieters R; Van Dongen JJ;
Leukemia; 2009 Jun; 23(6):1073-9. PubMed ID: 19212338
[TBL] [Abstract][Full Text] [Related]
50. CloneRetriever: An Automated Algorithm to Identify Clonal B and T Cell Gene Rearrangements by Next-Generation Sequencing for the Diagnosis of Lymphoid Malignancies.
Halper-Stromberg E; McCall CM; Haley LM; Lin MT; Vogt S; Gocke CD; Eshleman JR; Stevens W; Martinson NA; Epeldegui M; Holdhoff M; Bettegowda C; Glantz MJ; Ambinder RF; Xian RR
Clin Chem; 2021 Nov; 67(11):1524-1533. PubMed ID: 34491318
[TBL] [Abstract][Full Text] [Related]
51. Molecular biology strategies to detect residual disease.
Garcés-Eisele J
Hematology; 2012 Apr; 17 Suppl 1():S66-8. PubMed ID: 22507783
[TBL] [Abstract][Full Text] [Related]
52. Monitoring minimal residual disease in pediatric hematologic malignancies.
Campana D
Clin Adv Hematol Oncol; 2007 Nov; 5(11):876-7, 915. PubMed ID: 18185484
[No Abstract] [Full Text] [Related]
53. Accurate Sample Assignment in a Multiplexed, Ultrasensitive, High-Throughput Sequencing Assay for Minimal Residual Disease.
Bartram J; Mountjoy E; Brooks T; Hancock J; Williamson H; Wright G; Moppett J; Goulden N; Hubank M
J Mol Diagn; 2016 Jul; 18(4):494-506. PubMed ID: 27183494
[TBL] [Abstract][Full Text] [Related]
54. Interlaboratory Analytical Validation of a Next-Generation Sequencing Strategy for Clonotypic Assessment and Minimal Residual Disease Monitoring in Multiple Myeloma.
Medina A; Jiménez C; Puig N; Sarasquete ME; Flores-Montero J; García-Álvarez M; Prieto-Conde I; Chillón C; Alcoceba M; González-Calle V; Gutiérrez NC; Jacobsen A; Vigil E; Hutt K; Huang Y; Orfao A; González M; Miller J; García-Sanz R
Arch Pathol Lab Med; 2022 Jul; 146(7):862-871. PubMed ID: 34619755
[TBL] [Abstract][Full Text] [Related]
55. Measurable residual disease in acute lymphoblastic leukemia: methods and clinical context in adult patients.
Saygin C; Cannova J; Stock W; Muffly L
Haematologica; 2022 Dec; 107(12):2783-2793. PubMed ID: 36453516
[TBL] [Abstract][Full Text] [Related]
56. Whole-genome sequencing facilitates patient-specific quantitative PCR-based minimal residual disease monitoring in acute lymphoblastic leukaemia, neuroblastoma and Ewing sarcoma.
Subhash VV; Huang L; Kamili A; Wong M; Chen D; Venn NC; Atkinson C; Mayoh C; Venkat P; Tyrrell V; Marshall GM; Cowley MJ; Ekert PG; Norris MD; Haber M; Henderson MJ; Sutton R; Fletcher JI; Trahair TN
Br J Cancer; 2022 Feb; 126(3):482-491. PubMed ID: 34471258
[TBL] [Abstract][Full Text] [Related]
57. Fast multiclonal clusterization of V(D)J recombinations from high-throughput sequencing.
Giraud M; Salson M; Duez M; Villenet C; Quief S; Caillault A; Grardel N; Roumier C; Preudhomme C; Figeac M
BMC Genomics; 2014 May; 15(1):409. PubMed ID: 24885090
[TBL] [Abstract][Full Text] [Related]
58. A competitive PCR-based method using TCRD, TCRG and IGH rearrangements for rapid detection of patients with high levels of minimal residual disease in acute lymphoblastic leukemia.
Guidal C; Vilmer E; Grandchamp B; Cavé H
Leukemia; 2002 Apr; 16(4):762-4. PubMed ID: 11960365
[No Abstract] [Full Text] [Related]
59. Validation of a PCR-Based Next-Generation Sequencing Approach for the Detection and Quantification of Minimal Residual Disease in Acute Lymphoblastic Leukemia and Multiple Myeloma Using gBlocks as Calibrators.
Van der Straeten J; De Brouwer W; Kabongo E; Dresse MF; Fostier K; Schots R; Van Riet I; Bakkus M
J Mol Diagn; 2021 May; 23(5):599-611. PubMed ID: 33549860
[TBL] [Abstract][Full Text] [Related]
60. Minimal residual disease.
Radich J
Curr Opin Hematol; 1995 Jul; 2(4):300-4. PubMed ID: 9372011
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
